Sector Gamma AS Has $3.29 Million Holdings in Edwards Lifesciences Corporation $EW

Sector Gamma AS trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 65.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 42,000 shares of the medical research company's stock after selling 81,000 shares during the quarter. Sector Gamma AS's holdings in Edwards Lifesciences were worth $3,285,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $266,000. Wealth Enhancement Advisory Services LLC grew its position in Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after buying an additional 9,188 shares in the last quarter. Oppenheimer Asset Management Inc. increased its stake in Edwards Lifesciences by 23.5% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 21,699 shares of the medical research company's stock worth $1,573,000 after acquiring an additional 4,125 shares during the period. Asset Management One Co. Ltd. raised its holdings in Edwards Lifesciences by 3.4% in the 1st quarter. Asset Management One Co. Ltd. now owns 250,089 shares of the medical research company's stock valued at $18,126,000 after acquiring an additional 8,271 shares in the last quarter. Finally, Golden State Wealth Management LLC raised its holdings in Edwards Lifesciences by 125.0% in the 1st quarter. Golden State Wealth Management LLC now owns 5,135 shares of the medical research company's stock valued at $372,000 after acquiring an additional 2,853 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $76.62 on Friday. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company has a market cap of $44.99 billion, a price-to-earnings ratio of 11.02, a PEG ratio of 3.69 and a beta of 1.05. The firm has a 50 day simple moving average of $77.41 and a 200 day simple moving average of $76.30.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the business earned $0.70 earnings per share. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Truist Financial raised their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Mizuho boosted their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Finally, Piper Sandler lifted their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $87.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.